SCHEDULE: Vanguard Group Reports 0% Stake in Eton Pharmaceuticals
Beneficial Ownership Report Amendment
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Eton Pharmaceuticals Inc. following an internal realignment.
Summary
- The Vanguard Group filed an Amendment No. 1 to its Schedule 13G for Eton Pharmaceuticals Inc. Common Stock.
- The filing reports 0% beneficial ownership of Eton Pharmaceuticals Inc. Common Stock by The Vanguard Group.
- This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will now report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these disaggregated subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative update from The Vanguard Group regarding its internal reporting structure, with no direct impact on Eton Pharmaceuticals' operational or financial performance.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that institutional investors like The Vanguard Group frequently adjust their reported beneficial ownership due to internal restructuring or changes in investment mandates. This specific filing reflects an internal reporting realignment at Vanguard, where certain subsidiaries will now report their holdings separately, rather than indicating a complete divestment of Eton Pharmaceuticals shares by the entire Vanguard entity.
Stakeholder Impact
- Shareholders of Eton Pharmaceuticals Inc. may note the change in reported beneficial ownership by The Vanguard Group, though the underlying holdings by Vanguard's various funds may still exist and will now be reported separately.
Key Dates
| Date | Description |
|---|---|
| 2026-01-12 | Date of internal realignment at The Vanguard Group, Inc. |
| 2026-03-13 | Date of event which requires filing of this statement (beneficial ownership change). |
| 2026-03-26 | Date of signature for the filing. |
Keywords
Eton Pharmaceuticals Inc, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.